Inflammatory CAA and AD Biomarkers International Network - icaβ

09/08/2023

Is ARIA Treatment-Induced CAA-ri?

Alzheimer's Association Interview Fabrizio Piazza

https://www.alzforum.org/news/conference-coverage/aria-inflammatory-reaction-vascular-amyloid

Is ARIA Treatment-Induced CAA-ri? here is my comments for Alzforum story. Thank you Madolyn Bowman Rogers for the great interview and for having cited so…

07/08/2023

As the iCAB International Network and the Laboratory of and AD and at Università degli Studi di Milano-Bicocca, we are proud to be among the certificated Academic Members of the European Alzheimer's Disease Consortium ( ), a fully functional network of over 70 European Centres of Excellence working in the field of and related and .

https://lnkd.in/geSQn9N

Fabrizio Piazza Università degli Studi di Milano-Bicocca

03/08/2023

Despite landmark antibody approval, research into potentially serious brain swelling and bleeding still lags

13/01/2023

In their article, Cogswell et al[1][1] offered a valuable critical reflection on the past, present, and future challenges in the application of detection and reporting recommendations for amyloid-related imaging abnormalities (ARIAs) associated with amyloid β (Aβ)-lowering immunotherapy for

09/08/2022

https://m.facebook.com/story.php?story_fbid=10229062024161372&id=1416153937

Background and Objectives: Amyloid-related imaging abnormalities suggestive of vasogenic edema or sulcal effusion (ARIA-E) are the most common adverse events complicating Alzheimer’s disease (AD) immunotherapy with anti-amyloid-beta (Aβ) monoclonal antibodies (mAbs). ARIA-E can also occur spontan...

06/06/2022

Our last manuscript on ARIA, which is the iatrogenic manifestation of CAA-related inflammation but here presumably induced by immunotherapy with Therapeutic amyloid-lowering antibodies for Alzheimer's disease immunotherapy.
https://m.facebook.com/story.php?story_fbid=10228705416686408&id=1416153937

Introduction Amyloid-related imaging abnormalities with edema/effusion (ARIA-E) are commonly observed with anti-amyloid therapies in Alzheimer's disease. We developed a semi-mechanistic, in silico m...

25/04/2022

Our latest commentary on the need of Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities and CAAri is finally out on JAMA Neurology.

https://jamanetwork.com/journals/jamaneurology/fullarticle/2791266?guestAccessKey=bf0c6003-0c44-400e-bdb4-95f8c8ad16be&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=042522

To the Editor Hall et al1 describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA....

29/03/2022

Per gli amici del triveneto, ci vediamo il 22 Aprile!

Negli ultimi anni, si è via via affermato il ruolo chiave dei processi infiammatori nell’insorgenza di molti disordini neurologici, anche